Macrocyclic lactone compounds and methods for their use
Inventors
Yan, John • Zheng, Xiaoxia • Bhat, Vinayak D.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.
Core Innovation
The disclosure describes modified macrocyclic lactones, including demethylated, hydroxylated, epoxide, N-oxide, ring-opened, and seco forms, exemplified by 16-O-demethyl rapamycin and defined structural variants. These macrolide compounds encompass variations in substituents, stereochemistry, and oxidation states at multiple positions, including hydroxyalkyl, triazole, phosphate, and hydroxyl substitutions. Compositions comprising these compounds retain immunosuppressive and antiproliferative properties.
The disclosure further provides methods for treating or preventing acute or chronic transplant rejection by administering a therapeutically effective amount of the specified compound, salt, isomer, or N-oxide to a subject. Delivery modes encompass systemic administration, local delivery, and site-specific intracorporeal implants such as drug-eluting stents and vascular prostheses. Documented evaluations include smooth-muscle-cell proliferation inhibition, sustained compound release, porcine stent stenosis measurements, and a four-month clinical stent follow-up study.
Claims Coverage
The claims identify one independent claim comprising one main inventive feature directed to treating or preventing acute or chronic transplant rejection.
Administration of a specified compound for transplant rejection
A method for treating or preventing acute or chronic transplant rejection, comprising administering to a subject in need thereof a therapeutically effective amount of a specified compound, or a salt, isomer, or N-oxide thereof, thereby treating or preventing transplant rejection.
The independent claim covers administration of the specified compound, salt, isomer, or N-oxide to treat or prevent acute or chronic transplant rejection, with dependent claims providing further refinements concerning specific transplant types, systemic or local delivery modes, formulations, excipients, polymers, stereochemistry, and implants.
Stated Advantages
The described compounds are stated to retain immunosuppressive and antiproliferative properties.
The claimed method is directed to treating or preventing acute or chronic transplant rejection.
The description reports inhibition of smooth-muscle-cell proliferation and results from stent studies, including a four-month in-stent late lumen loss measurement in a 15-subject clinical study.
Documented Applications
Treatment or prevention of acute or chronic rejection following organ or tissue transplantation, including heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, and corneal transplants.
Implant-based delivery for transplant rejection treatment or prevention, including applications involving vascular prostheses and drug-eluting stents.
Cell-proliferation inhibition.
Ophthalmic treatment.
Interested in licensing this patent?